These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 32589113)

  • 1. From personalized to precision cancer medicine.
    Baltagiannis EG; Kyrochristos ID; Ziogas DE; Goussia A; Mitsis M; Roukos DH
    Per Med; 2020 Jul; 17(4):245-250. PubMed ID: 32589113
    [No Abstract]   [Full Text] [Related]  

  • 2. Sequencing Circulating Cell-Free DNA: The Potential to Refine Precision Cancer Medicine.
    Tie J; Gibbs P
    Clin Chem; 2016 Jun; 62(6):796-8. PubMed ID: 27117467
    [No Abstract]   [Full Text] [Related]  

  • 3. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.
    Bennett CW; Berchem G; Kim YJ; El-Khoury V
    Oncotarget; 2016 Oct; 7(43):71013-71035. PubMed ID: 27589834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enabling Precision Oncology Through Precision Diagnostics.
    Brown NA; Elenitoba-Johnson KSJ
    Annu Rev Pathol; 2020 Jan; 15():97-121. PubMed ID: 31977297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.
    Morganti S; Tarantino P; Ferraro E; D'Amico P; Duso BA; Curigliano G
    Adv Exp Med Biol; 2019; 1168():9-30. PubMed ID: 31713162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation sequencing: from conventional applications to breakthrough genomic analyses and precision oncology.
    Ziogas DE; Kyrochristos ID; Roukos DH
    Expert Rev Med Devices; 2018 Jan; 15(1):1-3. PubMed ID: 29284319
    [No Abstract]   [Full Text] [Related]  

  • 7. New insights from the widening homogeneity perspective to target intratumor heterogeneity.
    Tong M; Deng Z; Zhang X; He B; Yang M; Cheng W; Liu Q
    Cancer Commun (Lond); 2018 May; 38(1):17. PubMed ID: 29764517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cancer: three eras of personalized medicine].
    Jordan B
    Med Sci (Paris); 2017 Oct; 33(10):905-908. PubMed ID: 28994388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
    Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Personalized medicine in oncology].
    Lörsch AM; Jung J; Lange S; Pfarr N; Mogler C; Illert AL
    Pathologie (Heidelb); 2024 May; 45(3):180-189. PubMed ID: 38568256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life.
    Morganti S; Tarantino P; Ferraro E; D'Amico P; Viale G; Trapani D; Duso BA; Curigliano G
    Crit Rev Oncol Hematol; 2019 Jan; 133():171-182. PubMed ID: 30661654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and Outlooks in Precision Medicine: Expectations Versus Reality.
    Yan RE; Greenfield JP
    World Neurosurg; 2024 Oct; 190():573-581. PubMed ID: 39425299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. microRNAs and Personalized Medicine: Evaluating Their Potential as Cancer Biomarkers.
    Saumet A; Lecellier CH
    Adv Exp Med Biol; 2015; 888():5-15. PubMed ID: 26663176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision oncology in patients with nonmetastatic disease: emerging reality or illusion.
    Antoniou P; Ziogas DE; Mitsis M; Roukos DH
    Future Oncol; 2019 Jun; 15(16):1805-1810. PubMed ID: 31170806
    [No Abstract]   [Full Text] [Related]  

  • 16. Researchers push for personalized tumour vaccines.
    Ledford H
    Nature; 2016 Apr; 532(7600):425. PubMed ID: 27121818
    [No Abstract]   [Full Text] [Related]  

  • 17. Conquering the challenges of genotypic and phenotypic tumor heterogeneity to realize the promise of personalized cancer therapy: the role of academia.
    Merajver S; Phadke S; Soellner M
    Trans Am Clin Climatol Assoc; 2017; 128():169-179. PubMed ID: 28790501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized medicine in cancer: where are we today?
    Turnbull AK
    Future Oncol; 2015; 11(20):2795-8. PubMed ID: 26344657
    [No Abstract]   [Full Text] [Related]  

  • 19. Steps forward for cancer precision medicine.
    Salgado R; Moore H; Martens JWM; Lively T; Malik S; McDermott U; Michiels S; Moscow JA; Tejpar S; McKee T; Lacombe D;
    Nat Rev Drug Discov; 2018 Jan; 17(1):1-2. PubMed ID: 29170471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized virotherapy in cancer.
    Cafferata EG; Podhajcer OL
    Aging (Albany NY); 2015 May; 7(5):288-9. PubMed ID: 26022702
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.